Strategies for implementing long‐acting cabotegravir for PrEP in US clinics serving Black women: interim healthcare provider findings from the EBONI studyKatherine Nelson, Nanlesta Pilgrim, Denise Sutherland‐Philips et al.|Journal of the International AIDS Society|2025Cited by 4
1559. Healthcare Staff Perceptions of Feasibility and Acceptability on Implementing Injectable HIV Pre-exposure Prophylaxis into Standard of Care: Baseline Results from the PrEP Implementation Study for Cabotegravir Long Acting for Men in the Real World (PILLAR)Julian A Torres, Nanlesta Pilgrim, Dima Dandachi et al.|Open Forum Infectious Diseases|2023Cited by 0
P-1899. Improvement in Provider Experiences from Baseline to Month 12 with Integrating Cabotegravir Long-Acting (CAB LA) for PrEP into Care in an Implementation Science Trial (PILLAR)Taimur Khan, Nanlesta Pilgrim, Jonathan M. L. White et al.|Open Forum Infectious Diseases|2025Cited by 0